Once released, the OMVs target to inflammatory macrophages and delivered Cas9 RNPs to disrupt TNF-α expression, resulting in marked alleviation of colitis symptoms in inflammatory bowel disease models (Lin et al., 2024). This evidence concerns the gene TNF and colitis.